ABT · Abbott Laboratories
Price
Snapshot
50 fields · last close| Market Cap | $181.1B |
| P/E | 33.41 |
| Float | 1.72B |
| Beta | 0.55 |
| Volatility | 13.8% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 77.2 |
| Price | 104.41 |
| Change | −0.46% |
| Prev Close | 104.89 |
| Open | 105.00 |
| Day Low | 104.09 |
| Day High | 105.46 |
| Avg Vol | 9 |
| Avg $ Vol | $991.2M |
| 52W High | 133.34 |
| 52W Low | 81.97 |
| 52W Pos | 43.7% |
| From High | −21.70% |
| From Low | +27.38% |
| Max DD 1Y | −36.78% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +3.52% |
| SMA 50 | −1.44% |
| SMA 200 | +1.63% |
| RSI (14) | 58.4 |
| Vol 30D | 21.5% |
| Vol 90D | 29.2% |
| 1Y Range | 82–133 |
| Daily bars | 744 |
| Perf Week | +6.28% |
| Perf Month | +2.27% |
| Perf Quarter | +3.97% |
| Perf Half Y | +8.13% |
| Perf Year | −19.13% |
| Perf YTD | −15.93% |
| Prev Day | −0.46% |
| Clavix | B+ |
| Debt / Eq | 0.25 |
| Curr Ratio | 1.58 |
| Int Cover | 19.2× |
| FCF Margin | 16.7% |
| Rev Growth | +5.7% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 24 / 49 |
What ABT does
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test.
In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices.
The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915.
Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Clavix risk grade
regraded every trading dayABT grades B+, 77.2 of 100. Steadiest on Macro Resilience (66), most exposed on Sector Resilience (58, mixed). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 24 of 49 in Health Care by Clavix score.
How rough the ride is
| ABT | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.55 | 0.84 |
| Volatilityannualized | 13.8% | 21.1% |
| Max drawdown, past yearworst peak-to-trough fall | −36.8% | — |
| Typical daily movemedian absolute daily change | 0.84% | — |
| Days beyond ±3%of the last 252 sessions | 13 (5%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ABT | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.55 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ABT | |
|---|---|
| 1 week | +6.3% |
| 1 month | +2.3% |
| Year to date | −15.9% |
| 1 year | −19.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ABT | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 21 Aug |
| Average score0 most bearish, 100 most bullish | 55 |
| Bullish · bearisharticles above 60 · below 40 | 17 · 9 |
| Directionarticles whose tone is improving vs worsening | 17 ↑ 9 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| ABT | |
|---|---|
| Revenue growthyear over year | +5.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAn analyst argues that Abbott's stock could more than double by 2036, citing the company's roughly 10% annual earnings-per-share growth over the past decade and applying a more conservative 8% growth rate for the forecast. The author says they added ABT to their own portfolio.
Abbott announced a new product, Ensure Max Protein 3-in-1 Muscle Support, a daily powder that combines 30 grams of protein, 5 grams of creatine monohydrate, and 3 grams of calcium HMB in one serving. It is available in chocolate and vanilla at major U.S. retailers.
Abbott received FDA approval for new patient-facing features in its CardioMEMS heart failure system, allowing U.S. patients for the first time to view lung-artery pressure readings and get medication updates through a smartphone app called CardioGuide HF.
Abbott has launched SimpleScreen CRC, a new blood-based test for colorectal cancer screening that the FDA has approved for adults at average risk of the disease. The test adds a blood option to Abbott's existing stool-based Cologuard Plus test.
Abbott Laboratories launched SimpleScreen CRC in the US, an FDA-approved blood-based colorectal cancer screening test aimed at average-risk adults who decline traditional screening methods. The company's share price has fallen about 10.2% over the past month but is up 9.5% over the past 90 days.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ISRG | Intuitive Surgical Inc | B- | $151.2B | 47.42 | 1.46 | Compare |
| MDT | Medtronic PLC | A- | $122.1B | 23.15 | 0.59 | Compare |
| CVS | CVS Health Corp | A- | $118.4B | 23.91 | 0.59 | Compare |
| MCK | McKesson Corp | B+ | $116.4B | 25.30 | 0.31 | Compare |
| SYK | Stryker Corp | B | $112.5B | 29.93 | 0.79 | Compare |
| HCA | HCA Healthcare Inc | B+ | $101.4B | 14.83 | 1.12 | Compare |
| ELV | Elevance Health Inc | B+ | $92.91B | 18.78 | 0.64 | Compare |
| UNH | UnitedHealth Group Inc | B+ | $365.0B | 23.39 | 0.54 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.